IDH1 and oligodendroglioma: In contrast, IDH-mutant astrocytomas (~10–15%) and oligodendrogliomas harboring 1p/19q co-deletion (~4–5%) exhibit significantly better outcomes, with a median OS ranging from 8 to 12 years or longer.